StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Biosimilars Included in Other Product Sales by Quarter

Biosimilars Included in Other Product Sales — Worldwide ($M) ($M)

QuarterlyAnnual

Amgen Biosimilars Included in Other Product Sales: $199M in Q2 2026, up 15.7% from a year earlier.

Latest, Q2 2026
199
Period ended Jun 30, 2026
Change on a year earlier
+15.7%
172 in Q2 2025
History
15 quarters
Since Q4 2022
Sources
11
Documents cited below

Where the Q2 2026 figure comes from

“|| (2) Other products consist of Aimovig ® , AVSOLA ® , KANJINTI ® , EPOGEN ® , BKEMV ® /BEKEMV ™ , RIABNI ® , IMLYGIC ® , NEUPOGEN ® , RAYOS ® , DUEXIS ® , Sensipar ® /Mimpara ™ , Corlanor ® , and PENNSAID ® . Biosimilars total $199 million in Q2 ’26 and $172 million in Q2 ’25. Rare Disease products total ($3) million in Q2 ’26 and $4 million in Q2 ’25.”

Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K MD&A Other Product Sales by Geographic Region Footnote.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBiosimilars Included in Other Product Sales — Worldwide ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026199+15.7%Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026185+8.2%Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 2025189-13.3%Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 2025151+2.0%Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 2025172-6.0%Form 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 2025171-2.8%Form 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗
Q4 2024Dec 31, 2024218+134.4%Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 2024148+42.3%Form 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 2024183+40.8%Form 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2024Mar 31, 2024176+45.5%Form 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗
Q4 2023Dec 31, 202393+78.8%Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 2023104–Form 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2023Jun 30, 2023130–Form 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2023Mar 31, 2023121–Form 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗
Q4 2022Dec 31, 202252–Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗

Cite this data

StockData. (2026). Amgen Biosimilars Included in Other Product Sales ($M), quarterly Q4 2022–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-biosim-in-other-ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.